Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Creation of a Weakly Virulent Strep A Mutant May Boost Vaccine Development

By BiotechDaily International staff writers
Posted on 23 Jun 2014
Print article
Image: Electron micrograph, false color, of group A Streptococcus bacteria (Photo courtesy of the University of California, San Diego).
Image: Electron micrograph, false color, of group A Streptococcus bacteria (Photo courtesy of the University of California, San Diego).
Creation of a mutated variety of Group A Streptococcus (GAS) bacteria with reduced virulence but complete immunological expression may pave the way for development of a safe vaccine to prevent infections such as strep throat, necrotizing fasciitis, and rheumatic heart disease, which are caused by these organisms.

All GAS serotypes express the Lancefield group A carbohydrate (GAC), comprising a polyrhamnose backbone with an immunodominant N-acetylglucosamine (GlcNAc) side chain, which is the basis of rapid diagnostic tests. No biological function has so far been attributed to this conserved antigen.

Investigators at the University of California, San Diego (USA) recently identified the genetic locus for GAC and used this knowledge to create a strep A mutant that lacked the GlcNAc side-chain addition. They reported in the June 11, 2014, issue of the journal Cell Host & Microbe that this mutant was significantly less virulent than the wild type organism in two infection models, in association with increased sensitivity to neutrophil killing, platelet-derived antimicrobials in serum, and the antimicrobial peptide LL-37.

The investigators also showed that antibodies to GAC lacking the GlcNAc side chain and containing only polyrhamnose promoted killing of multiple GAS serotypes and protected against systemic GAS challenge after passive immunization.

These findings demonstrated that the Lancefield antigen played a functional role in GAS pathogenesis, and that a deeper understanding of this unique polysaccharide has implications for vaccine development.

“It is satisfying to find that a fundamental observation regarding the genetics and biochemistry of the pathogen can have implications not only for strep disease pathogenesis, but also for vaccine design,” said senior author Dr. Victor Nizet, professor of pediatrics and pharmacy at the University of California, San Diego.

“Most people experience one or more painful strep throat infections as a child or young adult. Developing a broadly effective and safe strep vaccine could prevent this suffering and reduce lost time and productivity at school and work, estimated to cost two billion USD annually.”

Related Links:
University of California, San Diego



Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.